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Following partial pancreaticoduodenectomy for periampullary and pancreatic cancer, the complication
and mortality rates are particularly high. Various approaches have aimed at improving the postoperative
result, with less than complete success. The discouraging results of others, and our own dissatisfaction,
led us to evaluate an atraumatic, sutureless method for management of the residual gland. Following
head resection, the remaining pancreas is occluded with a fibrin sealant (Tisseel c, Immuno AG,
Vienna) via injection into the pancreatic duct, which is then ligated and left free in the peritoneal cavity.
Among 44 patients treated with this method, there were no perioperative deaths. Three patients
developed local complications (2 fistulae, 1 pancreatitis) due to technical errors that presumably resulted
in incomplete occlusion. Evaluation of patients after two to three years indicates that the endocrine
function of the pancreas has been largely conserved despite ductal occlusion.
KEY WORDS" Complications in pancreatic surgery, Whipple operation, occlusion with fibrin sealant,
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INTRODUCTION
Pancreatic surgery is generally accompanied by a high complication rate and the
complication and mortality rates following partial pancreaticoduodenectomy for
malignant indication are particularly high
1-9 (Table 1). The average perioperative
mortality rate cited for the Whipple procedure has been around 14%, with a range
between 3% and 24%, and postoperative complications have been observed in
almost half the patients. However, in the past decade morbidity and mortality rates
have been falling3’5’6’8’1.
The poor results seen following the Whipple operation are due largely to leakage
3568910 from the pancreaticoenteric anastomosis
A variety of surgical techniques have been tried in order to reduce the incidence
of pancreatic fistulas resulting from the lytic effects of pancreatic enzymes on the
pancreaticojejunostomy4’6’8’9’1
The open pancreatic stump procedure,
11 produced relatively poor results. Its
advantage was the absence of perioperative mortality. Splinting (stenting) of the
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pancreatic duct has also been attempted as a means of protecting the pancreati-
coenteric anastomosis from the pancreatic enzymes6’1.
Pancreatic duct ligation, combined with sealing of the surface of the resection
area with fibrin sealant also did not produce the desired result and in some patients,
reflux resulted in "retention pancreatitis" and subsequent pancreatic tistulae12’13.
Some major centers have abandoned the Whipple procedure in favor of total
pancreatectomy because of problems related to pancreaticojejunal dehiscence and
the possibility of residual cancer in the stump4’14. In contrast to van Heerden, we
have not encountered evidence of malignant spreads to the pancreatic tail, either
on pathologic sections or from clinical evidence. Kummerle was also unable to find
evidence of multicentricity4.
Pharmacologic agents such as somatostatin, terbutaline, glucagon, atropine and
calcitonin have been employed to halt pancreatic exocrine activity15’16. A new
approach, the pancreatic duct occlusion (PDO) with synthetic materials such as
prolamine (Ethibloc) and neoprene has been used in both pancreatic cancer and
transplantation surgery with reported success in blocking the pancreatic ductal
system, but with evidence of occasional transient pancreatic fistulae and/or pro-
gressive failure of pancreatic endocrine function17’18.
A desire to decrease the morbidity and mortality due to leakage at the pancreati-
cojejunal anastomosis led us to evaluate an atraumatic method for pancreatic
stump management which did not involve attachment of the pancreas to the
gastrointestinal tract. Based on the knowledge that pancreatic duct stasis leads to
atrophy of the exocrine glands, we decided to induce occlusion of the pancreatic
ductal system. We chose a physiologic agent that we hoped would not elicit foreign
body reaction in the pancreatic sump and subsequent fibrosis of the remaining
gland with damage to the islets.
MATERIAL AND METHOD
Fibrin Sealant
The fibrin sealant (Tisseel c, Immuno AG, Vienna, Austria) has been available for
Table 1 Perioperative complication and mortality rates associated with pancreaticoduodentectomy for
malignant indication
Complications Mortality
Author (Ref.) Year % %
Schapiro (1) 1975 50 8
Nakase (2) 1977 49 21
Warren (3) 1983 (1951-60) 14
(1971-80) 3, 4
Kummerle & Ruckert (4) 1984 20
Van Heerden (5) 1984 33 4
Grace et al. (6) 1986 (1975-79) 49 10
(1980-84) 26 2
Tarazi et al. (7) 1986 > 40 7
Christ et al. (8) 1987 (1969-80) 59 24
(1981-86) 36 2
Trede & Schwall (9) 1988 32 3PANCREATIC MALIGNANCY 253
use in Europe since 1976, in Canada since 1986, and in the United States, under an
FDA-approved IND since 1986. It is provided as a multicomponent system from
which two solutions are prepared. The sealant is obtained from human plasma and
its major constituents are concentrated fibrinogen, factor XIII and fibronectin.
Shortly before use, the sealer protein concentrate is dissolved in a solution of an
antifibrinolytic agent, aprotinin, which has been warmed to 37<o> C. The
clotting activator is dried bovine thrombin dissolved in a calcium chloride solution.
A high thrombin concentration (500U/ml) is selected to ensure rapid solidification
of the sealant, and a high aprotinin concentration (10<ts>000 U/ml) is used in
order to prevent premature dissolution of the fibrin sealant by pancreatic enzymes.
When prepared for use, the solutions are drawn into separate syringes which are
then mounted on a special Y-connector which mixes them as they are expelled into
the appropriate area of the operating field.
With regard to safety from virus infection, data from the multicenter cardiac
study in the United States (Rousou, J., Levitsky, S., Gonzalez-Lavin, L.,
Cosgrove, D., Magilligan, D., et al. Randomized Clinical Trial of Fibrin Sealant in
Patients Undergoing Resternotomy of Reoperation after Cardiac Operations. J.
Thorac Cardiovasc. Surg., 1989: 97: 194-203) indicated no HIV or HBsAg
conversion among 33 patients, and evidence of ALT elevation only in one patient
who had been massively transfused.
SURGICAL PROCEDURE
Following Whipple resection, the remaining ducts are occluded with fibrin sealant.
Approximately three to five ml fibrin sealant are injected into the main pancreatic
duct, either through a blunt needle or a thin plastic catheter, beginning as deeply as
possible in the remaining glandular tissue. As the needle or catheter is slowly
withdrawn, fibrin sealant is continously injected until small fibrin thrombi appear
on the resection surface. The pancreatic duct is then ligated and the resection area
is covered with an additional layer of sealant. Collagen fleece may be applied if
hemorrhage is difficult to control (Figures 1-4).
PATIENTS
This method was employed in 44 consecutively operated patients (25 male, 19
female) undergoing partial pancreaticoduodenectomy for malignancy. There were
5 patients with carcinoma of the common bile duct, 15 with ampullary carcinoma,
and 24 patients with carcinoma of the head of the pancreas. The average age was
67.3 years and 74% of the patients were older than 70 years; there was no patient
selection.
RESULTS
There were no perioperative deaths among the 44 patients. One patient developed
clinical evidence of persistent necrotizing pancreatitis, necessitating total pancrea-
tectomy. Two patients developed pancreatic fistulas, probably caused by incom-
plete occlusion. With conservative therapy, these receded within 2 to 4 weeks post-
surgery. Technical short-comings in these three patients, treated early in our series
probably led to incomplete occlusion and, as a consequence, retention pancreatitis.254 A.P. MARCZELL AND M. STIERER
Figure 1 Duct occlusion with Fibrin Sealant. (See colour plate at the back of this issue.)
In all patients, we noted a moderate elevation of serum amylase levels postopera-
tively (400 + 100 IE/1), which subsided after one week.
All patients lost their exocrine function. To compensate for the loss of pancreatic
enzymes, all surviving patients are given pancreatic granules as a dietary supple-
ment.
With regard to pancreatic endocrine function, all the patients with normal
glucose tolerance before surgery were unchanged postoperatively. Among those 6
patients with latent diabetes, demonstrated by abnormal preoperative glucose
tolerance tests, 3 developed manifest diabetes post surgery. Among these patientsPANCREATIC MALIGNANCY 255
Figure 2 Ligature of the occluded duct. (See colour plate at the back of this issue.)
the manifest diabetes can be also attributed to resection of intact pancreatic tissue.
After an observation period of 2 years, 14 of the surviving patients have normal
fasting blood sugar levels; 6 of these patients have normal fasting blood sugar after
3 years.
In a control series of 10 patients, pancreatic duct ligation was performed without
fibrin sealant occlusion. In this group, 2 patients died of necrotizing pancreatitis,
and 2 patients developed pancreatic fistulae. In ten consecutive patients treated at
our hospital by partial pancreaticoduodenectomy with pancreaticojejunal anasto-256 A.P. MARCZELL AND M. STIERER
Figure 3 Sealing of the resection surface with Fibrin Sealant. (See colourplate at the back ofthis issue.)
mosis, there were three deaths and four patients had significant perioperative
morbidity. Thus, the results obtained with pancreatic duct occlusion using fibrin
sealant were clearly superior to those seen either with simple duct ligation, or with
pancreaticojejunostomy in our patient population (Table 2).
DISCUSSION
The variety of techniques employed in performing Whipple’s operation indicate the
surgeons general dissatisfaction with the results of partial pancreaticoduodenec-
tomy for malignant indications. Even experts in the use of anastomotic techniques
encounter significant postoperative insufficiency rates. Of 824 cases reported inPANCREATIC MALIGNANCY 257
Figure 4 Sealing in combination with collagen fleece. (See colour plate at the back of this issue.)
Table 2 Complication and mortality rates following pancreaticoduodenectomy- with and without use
of fibrin sealant
Number of Perioperative Perioperative
Patients Mobidity Mortality
Fibrin sealant occlusion 44 3 (6, 8% 0
Duct ligation 10 2 (20%) 2 (20%)
Pancreaticojejunal anastomosis 12 4 (33%) 3 (25%)
Japan, Nakase
4 noted an incidence of dehiscence at the pancreaticojejunostomy
site of 14%, while other series report the incidence as being between 11% and
230/05-8. Dehiscence of the pancreaticoenteric anastomosis constitutes the most
frequent postoperative complication associated with partial pancreaticoduodenec-
tomy. What is more, it accounts for a high percentage of the perioperative deaths.
Our objective was to minimize postoperative pancreatitis and fistula formation
following pancreaticoduodenectomy, by using an atraumatic and fluid-tight pro-
cedure, while maintaining endocrine function via conservation of the pancreatic
tail. By the use of a low-viscosity fibrin sealant we are able to ensure the complete
occlusion of the duct system. The results we have described are very similar to
those of Ascherl and co-workers who conducted a comparative study which
demonstrated the advantages of fibrin sealing 19.258 A.P. MARCZELL AND M. STIERER
Occlusion of the pancreatic duct with prolamin does not yield uniformly favor-
able long term results, probably because the high and variable viscosity of this
material hampers complete occlusion of the collateral branches19. Furthermore,
occlusion with prolamin is usually followed by interstital fibrosis with subsequent
high-grade sclerosis of the exocrine pancreatic parenchyma beginning on the
second postoperative day, with significant alteration of the endocrine cell
function2.
The result is a worthwhile longterm result in endocrine function21. The disadvan-
tage of the fibrin-occlusion without anastomosis is the complete loss of exocrine
function and the continous need for treatment with pancreatic enzymes.
In the 44 patients in whom we have used fibrin sealant, we were able to reduce
significantly the perioperative mortality as well as the postoperative complication
rate of partial pancreaticoduodenectomy by employing fibrin sealant qcclusion of
the remaining pancreatic ducts. We continue to see satisfactory long-term results,
due to less interstitial reaction and fibrosis with this physiologic substance which
doesn’t induce a foreign body reaction.
Recently we have performed abdominal CAT scans of twelve patients. They
demonstrated that the pancreas remaining 3 years postoperatively-- has a
delicate parenchyma, which appears quite normal.
Simple handling and the atraumatic approach justify routine use of this method.
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INVITED COMMENTARY
Despite the remarkable decrease in operative morbi-mortality of pancreatoduode-
nectomy in specialized centers, complications from the pancreatojejunostomy
remains a concern. Patients with soft glands and pancreatic ducts of small diameter
are at high risk for developing complications. Techniques to attempt to minimize
these complications include the use of invaginating dunking techniques, the use of a
separate Roux-en-Y for the pancreatic anastomosis, the use of stents, the injection
and occlusion of the pancreatic duct with different polymers, the prophylactic use
of Somastatin, etc. However, it is likely that surgical expertise with pancreatoduo-
denectomy as developed in specialized centers is the primary reason for the
decrease in the complication rate from the pancreatojejunostomy. Nevertheless, in
the best of hands, the soft pancreas with a small pancreatic duct continues to
represent a major challenge. The experience with fibrin sealant for occlusion of the
pancreatic duct in the use of a nonanastomosed pancreatic stump technique of
pancreatoduodenectomy provides another alternative. Using this technique, the
authors reported no operative mortality in 44 patients, while the 22 patients that
had either duct ligation or pancreatojejunal anastomosis had a mortality of 23%.
This latter mortality, though, is very high for current standards and, therefore, the
difference with the fibrin sealant occlusion group appears more significant than if
compared to the mortality of less than 5% reported by other centers.
Although the data on endocrine function presented here is limited, it would tend
to support the idea that ductal occlusion in humans may have less effect on long-
term endocrine function than that reported in the animal model. However, for an
accurate assessment of the progressive loss of endocrine function as compared to a
sutured anastomosis, a prospective randomized trial would be needed.
The technique presented here should be looked upon as a possible option that
requires further assessment. The potential benefits of the fibrin sealant combined260 A.P. MARCZELL AND M. STIERER
with a suture anastomosis, either of the mucosa-to-mucosa or of the dunking type
would be of interest.
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